Indian pharmaceutical company Dr Reddy's Laboratories has filed a new application to test the Russian vaccine Sputnik V, reports RIA News.
As specified, we are talking about a multicenter, blind, randomized controlled trial.
Earlier, the General Comptroller of Medicines of India rejected the application of the pharmaceutical company to conduct the third phase of trials of the Russian drug and proposed to organize the second and third stages of the study.
After receiving regulatory approval, the Russian Direct Investment Fund is expected to supply 100 million doses of vaccine to India.
India is currently in the second phase of trials of the Covaxin and ZycovD coronavirus vaccines developed by Bharat Biotech and Zydus Cadila, as well as the ChAdOx1 vaccine, developed by the University of Oxford.
Recall that India is in second place in the world after the United States in terms of the number of coronavirus infections. Since the beginning of the pandemic, 7.2 million cases of COVID-19 have been identified in the country, more than 110 thousand people have died.
Earlier it was reported that clinical trials of the Russian vaccine "Sputnik V" started in Venezuela.